Barclays assigns an "overweight" rating and $356 target price to HCA Healthcare after strong Q4 earnings.
Barclays initiates coverage on HCA Healthcare with an "overweight" rating and $356.00 target price following better-than-expected Q4 earnings ($5.90 EPS, $17.30B revenue) and a $6B share buyback plan. Several other brokerages have issued reports on HCA, including Goldman Sachs downgrading to "neutral" and Raymond James raising its target price to $330. The consensus rating for HCA Healthcare is "Moderate Buy" with a target price of $308.26.
March 09, 2024
5 Articles